Skip to main content
AXSM
NASDAQ Life Sciences

Axsome Q3: Revenue Up 52% to $259.7M, Net Loss Narrows to $12.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$137.954
Mkt Cap
$7.124B
52W Low
$123
52W High
$260.19
52W Position info
12% above low
Off High info
47% below high
Rel. Volume info
3.3× avg
Market data snapshot near publication time

AXSM is trading near its 52-week low of $123 (12% above the low) on elevated volume (3.3× avg).

Summary

Axsome grew Q3 revenue 52% to $259.7 million and cut its net loss to $12.9 million, with $313.9 million of cash and the $70 million revolver repaid in October.


Key Events · Earnings and Guidance · AXSM

  • Q3 Revenue Jumps 52%

    Total revenues were $259.7 million versus $171.0 million a year earlier; AUVELITY contributed $207.6 million and SUNOSI $38.5 million.

  • Net Loss Narrows Sharply

    Net loss fell to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, in Q3 2025.

  • Cash Covers Twelve Months

    Cash and equivalents stood at $313.9 million at September 30, 2026, which management says funds anticipated operating requirements for at least twelve months.

  • Revolver Repaid in October

    The $70.0 million Blackstone revolver balance at quarter end was repaid in full in October 2026, leaving $20.0 million undrawn at September 30.


Analysis · AXSM · Life Sciences

The commercial model is scaling: total revenue reached $259.7 million versus $171.0 million a year ago, with AUVELITY alone at $207.6 million as the Alzheimer's-agitation launch adds volume. Net loss shrank to $12.9 million from $47.2 million, and the company ended September with $313.9 million in cash—enough, management says, to cover at least twelve months of operations. Two balance-sheet items matter for risk: the $70 million revolver was repaid in full in October, and the long-running stockholder derivative suit was dismissed with prejudice on October 13, 2026. The offset is spending—SG&A rose to $203.1 million from $150.2 million on the ADA launch, direct-to-consumer advertising and sales-force expansion—so profitability still depends on holding that revenue growth.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AXSM was trading at $137.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $123.00 to $260.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AXSM - Latest Insights

AXSM
Nov 02, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $144.53
Real-time Price: $135.00 info
Change: -$9.53 (-7%) info
Market Cap: $7.207B info
AXSM
Nov 02, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $148.02
Real-time Price: $135.00 info
Change: -$13.02 (-9%) info
Market Cap: $7.207B info
AXSM
Aug 10, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $220.89
Real-time Price: $135.00 info
Change: -$85.89 (-39%) info
Market Cap: $7.207B info
AXSM
Aug 10, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $207.20
Real-time Price: $135.00 info
Change: -$72.20 (-35%) info
Market Cap: $7.207B info
AXSM
Jul 15, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $229.00
Real-time Price: $135.00 info
Change: -$94.00 (-41%) info
Market Cap: $7.207B info